Remdesivir
Remdesivir Class of drug: Broad spectrum anti coronavirus Mechanism: it blocks the enzymes (RNA polymerase) needed by coronavirus to make its copies decreasing the viral load Current status: Experimental Indications: COVID-19 suspected or confirmed – requiring oxygen, mechanical ventilation or ECMO Dose: Intravenous- 200 mg on day 1 then 100 mg OD for total 5 days- if not on mechanical ventilation Duration 10 days if on mechanical ventilation Not recommended in severe renal failure Side Effects- Anaemia, nephrotoxicity, hepatotoxicity, Nausea, vomiting etc. FDA Status: Remdesivir is not an approved drug for SARS Cov-2 or any other infection. FDA has approved EUA (Emergency Use Authorisation) of Remdesivir for the hospitalised patients Bottom line: Remdesivir can be a drug to be tried in correct clinical setting Source: Drugs.com =========== Dr. Prashant Kumar